Organon and Co

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

492

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 8 drugs with upcoming expirations

Activity

Key Events

Aug 13, 2026TrialA Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Jun 23, 2026FDAProlia — PROLIA, XGEVA

Jun 16, 2026FDAGanirelix Acetate — FYREMADEL

Mar 25, 2026TrialA 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial

Feb 26, 2026FDARizafilm — RIZAFILM

Aug 29, 2025FDAProlia — BILPREVDA

4 more events

Jun 20, 2025FDACozaar — COZAAR

May 30, 2025FDAProlia — PROLIA, XGEVA

Jul 26, 2023TrialEffectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

Mar 13, 2023TrialA Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

17 patent groups across drugs · Source: FDA Orange Book

DrugExpires

ZetiaOct 30, 2025 ZetiaApr 30, 2026 ImplanonAug 28, 2026 Rayaldee3 patentsFeb 2, 2027 ZocorApr 26, 2027 Implanon2 patentsMay 31, 2027 Rayaldee8 patentsApr 25, 2028 ZocorFeb 23, 2030

9 more

ImplanonJul 28, 2030 RayaldeeSep 7, 2030 FosamaxDec 5, 2031 Rayaldee4 patentsMar 14, 2034 RizafilmJul 30, 2034 Vtama6 patentsMay 19, 2036 Vtama2 patentsNov 13, 2038 Vtama4 patentsNov 13, 2039 Cozaar3 patentsOct 7, 2041

Regulatory

Regulatory Timeline

20246 events

FDASep 23

Ganirelix Acetate — GANIRELIX ACETATE

Application NDA021057

FDAJul 26

Ganirelix Acetate — FYREMADEL

Application ANDA204246

FDAApr 9

Prolia — PROLIA, XGEVA

Application BLA125320

FDAMar 20

Ganirelix Acetate — GANIRELIX ACETATE

Application ANDA214996

FDAMar 5

Prolia — WYOST

Application BLA761362 (BLA)

FDAMar 5

Prolia — PROLIA, XGEVA

Application BLA125320

20259 events

FDAAug 29

Prolia — BILPREVDA

Application BLA761444 (BLA)

FDAJun 20

Cozaar — COZAAR

Application NDA020386

FDAMay 30

Prolia — PROLIA, XGEVA

Application BLA125320

FDAMay 22

Prolia — PROLIA, XGEVA

Application BLA125320

FDAApr 28

Prolia — PROLIA, XGEVA

Application BLA125320

FDAApr 23

Ganirelix Acetate — GANIRELIX ACETATE

Application ANDA218855

FDAMar 25

Prolia — CONEXXENCE

Application BLA761398 (BLA)

FDAMar 13

Cozaar — ARBLI

Application NDA218772 (NDA)

FDAFeb 13

Prolia — OSPOMYV

Application BLA761392 (BLA)

20265 events

FDAJun 23

Prolia — PROLIA, XGEVA

Application BLA125320

FDAJun 23

Prolia — PROLIA, XGEVA

Application BLA125320

FDAJun 16

Ganirelix Acetate — FYREMADEL

Application ANDA204246

FDAFeb 26

Rizafilm — RIZAFILM

Application NDA205394 (NDA)

FDAFeb 26

Rizafilm — RIZAFILM

Application NDA205394 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)